Anchor Innovation Medical (A.I.M.)
Country not established
- Devices
- 3
What Anchor Innovation Medical (A.I.M.) makes
Anchor Innovation Medical designs and manufactures devices for orthopedic and cardiovascular applications, including lead loop suturing tools and tension assist/suture cutter devices for cardiac procedures, as well as a knotless meniscal repair device for knee surgery.
The company’s products are classified as Class II medical devices under FDA regulations and are authorised via the 510(k) pathway. These devices are listed in the FDA’s 510(k) database, and the manufacturer is based in the United States.
Catalogue
A.I.M. Suture Anchor Ref K132461
Regimes: 510(k) Registry: 510(k)- Regimes: 510(k) Registry: 510(k)
A.I.M. Knotless Meniscal Repair Device Ref K133770
Regimes: 510(k) Registry: 510(k)
Frequently asked questions
How many devices does Anchor Innovation Medical (A.I.M.) have in the registry?
The registry currently lists 3 devices for Anchor Innovation Medical (A.I.M.). Devices recorded under merged duplicate company entries are counted once.
Which registries list Anchor Innovation Medical (A.I.M.)'s devices?
Among its 3 most recently registered devices, Anchor Innovation Medical (A.I.M.) has devices listed in FDA 510(k) (3 devices).
What risk classes do Anchor Innovation Medical (A.I.M.)'s devices fall under?
Among its 3 most recently registered devices, the classes recorded for Anchor Innovation Medical (A.I.M.)'s devices are Class II. Each device page shows its own class and authorisation.
What are the newest devices from Anchor Innovation Medical (A.I.M.) in the registry?
The most recently registered devices listed for Anchor Innovation Medical (A.I.M.) include A.I.M. SUTURE ANCHOR, A.I.M. Lead Loop Suturing Device (1), A.I.M. Tension Assist/Suture Cutter Device, A.I.M. Lead Loop Suturing Device (1) plus Tension Assist/Suture Cutter Device, A.I.M. Lead Loop Suturing Device (2), A.I.M. Lead Loop Suturing Device plus Tension Assist/Suture Cutter Device and A.I.M. KNOTLESS MENISCAL REPAIR DEVICE.